4.2 Article

Medications used disproportionately during pregnancy: Priorities for research on the risks and benefits of medications when used during pregnancy

期刊

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY
卷 30, 期 1, 页码 53-64

出版社

WILEY
DOI: 10.1002/pds.5131

关键词

childbearing age; drug safety; drug utilisation; pharmacoepidemiology; pregnancy

资金

  1. Australian Department of Industry, Innovation and Science [CRC-P439]
  2. National Health and Medical Research Council [1028543, 1060407]
  3. NSW Ministry of Health
  4. National Health and Medical Research Council of Australia [1060407] Funding Source: NHMRC

向作者/读者索取更多资源

The study identified medications that were disproportionately more or less used by pregnant women compared to women of childbearing age. Some medications, such as hydralazine, ondansetron, dalteparin sodium and ranitidine, were found to have the strongest associations with pregnancy. On the other hand, hormonal contraceptives and progestogens were less likely to be used during pregnancy.
Purpose To identify medications used disproportionately more or less among pregnant women relative to women of childbearing age. Methods Medication use among pregnant women in New South Wales, Australia was identified using linked perinatal and pharmaceutical dispensing data from 2006 to 2012. Medication use in women of childbearing age (including pregnant women) was identified using pharmaceutical dispensing data for a 10% random sample of the Australian population. Pregnant social security beneficiaries (n = 111 612) were age-matched (1:3) to female social security beneficiaries in the 10% sample. For each medication, the risk it was dispensed during pregnancy relative to being dispensed during an equivalent time period among matched controls was computed. Medications were mapped to Australian pregnancy risk categories. Results Of the 181 included medications, 35 were statistically significantly more commonly dispensed to pregnant women than control women. Of these, 23 are categorised as posing no increased risk to the foetus. Among medications suspected of causing harm or having insufficient safety data, the strongest associations were observed for hydralazine, ondansetron, dalteparin sodium and ranitidine. Use was less likely during pregnancy than control periods for 127 medications, with the strongest associations observed for hormonal contraceptives and progestogens. Conclusions Most medications found to be used disproportionately more by pregnant women are indicated for pregnancy-related problems. A large number of medications were used disproportionately less among pregnant women, where avoidance of some of these medications may pose a greater risk of harm. For many other medications avoided during pregnancy, current data are insufficient to inform this risk-benefit assessment.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.2
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据